castration-resistant prostate cancer (CRPC) | |
metastatic (mCRPC) - 1st line (L1) | |
pembrolizumab based treatment | KEYNOTE-921 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -